300 related articles for article (PubMed ID: 34659219)
1. Poor CD4
Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
Front Immunol; 2021; 12():732667. PubMed ID: 34659219
[No Abstract] [Full Text] [Related]
2. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
Front Immunol; 2021; 12():694759. PubMed ID: 34335606
[TBL] [Abstract][Full Text] [Related]
3. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
[TBL] [Abstract][Full Text] [Related]
4. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
McGuire KA; Miura K; Wiethoff CM; Williamson KC
Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
[TBL] [Abstract][Full Text] [Related]
5. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
6. Protein/AS01
Nielsen CM; Ogbe A; Pedroza-Pacheco I; Doeleman SE; Chen Y; Silk SE; Barrett JR; Elias SC; Miura K; Diouf A; Bardelli M; Dabbs RA; Barfod L; Long CA; Haynes BF; Payne RO; Minassian AM; Bradley T; Draper SJ; Borrow P
Cell Rep Med; 2021 Mar; 2(3):100207. PubMed ID: 33763653
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
[TBL] [Abstract][Full Text] [Related]
8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
9. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
[TBL] [Abstract][Full Text] [Related]
11. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
[TBL] [Abstract][Full Text] [Related]
12. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
13. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
[TBL] [Abstract][Full Text] [Related]
14. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
Mlambo G; Maciel J; Kumar N
Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
[TBL] [Abstract][Full Text] [Related]
15. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
[TBL] [Abstract][Full Text] [Related]
16. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.
Kumar R; Ledet G; Graves R; Datta D; Robinson S; Bansal GP; Mandal T; Kumar N
Pharm Res; 2015 Dec; 32(12):3827-36. PubMed ID: 26113235
[TBL] [Abstract][Full Text] [Related]
17. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
Kumar R; Angov E; Kumar N
Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
[TBL] [Abstract][Full Text] [Related]
19. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
